RPG Investment Advisory LLC Raises Holdings in Novo Nordisk A/S $NVO

RPG Investment Advisory LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 13.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 152,574 shares of the company’s stock after purchasing an additional 17,662 shares during the period. RPG Investment Advisory LLC’s holdings in Novo Nordisk A/S were worth $8,466,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of NVO. Lockheed Martin Investment Management Co. boosted its position in Novo Nordisk A/S by 179.4% during the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after purchasing an additional 27,900 shares during the period. Martin Capital Partners LLC lifted its stake in shares of Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after purchasing an additional 41,129 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth about $1,294,000. Acadian Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 15,919.9% in the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after buying an additional 1,038,137 shares during the period. Finally, Unified Investment Management acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $692,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent research reports. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. HSBC reiterated a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Wednesday, December 3rd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $53.33.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. launch: Novo made the Wegovy pill broadly available across 70,000+ U.S. pharmacies with a subsidized self?pay starting price (reported $149/month), positioning the first oral GLP?1 for rapid patient uptake and widening access — a clear revenue catalyst. Novo Nordisk’s Wegovy pill now broadly available across America (PR Newswire)
• Positive Sentiment: Market reaction and coverage: Media and equity analysts flagged the pill’s U.S. launch as a potential catalyst to “rekindle momentum” for NVO shares and noted immediate stock upticks on the news. First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. (CNBC)
• Positive Sentiment: Unusual options flow: Traders bought ~131,266 call options (about +37% vs. normal), indicating short?term bullish bets that could amplify upside if newsflow or early sales data are positive. (Options volume report)
• Neutral Sentiment: Regulatory outlook outside U.S.: The UK regulator is reviewing Novo’s oral Wegovy submission and could decide by year?end — a potential incremental upside, but timing is uncertain. UK regulator could issue decision by year-end (Reuters)
• Neutral Sentiment: Valuation/return debate: Commentary pieces are weighing mixed historical returns against arguments that NVO remains undervalued — this frames investor expectations but doesn’t change near?term sales dynamics. Valuation check after mixed returns (Yahoo Finance)
• Negative Sentiment: Executive departure: Novo’s U.S. head of public affairs has left, which raises near?term communications and stakeholder?management risk as the company scales a major product launch in its largest market. U.S. public affairs head leaves (Reuters)
• Negative Sentiment: Market skepticism: Some analysts argue the Wegovy pill may not be a game?changer for long?term revenue vs. injectables and competitive pressures, tempering expectations for sustained upside. Wegovy pill is not a game changer (Seeking Alpha)

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $56.21 on Wednesday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $250.98 billion, a price-to-earnings ratio of 16.34 and a beta of 0.66. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The business has a 50 day simple moving average of $49.22 and a 200-day simple moving average of $55.45.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The firm had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.